







| 카탈로그 번호 | HY036096 | ||||
|---|---|---|---|---|---|
| 종 반응성 | Human | ||||
| 응용 분야 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo | ||||
| 숙주 종 | Human | ||||
| 클론성 | Monoclonal | ||||
| 이소타입 | IgG1 | ||||
| 클론 ID | JST-TFR09 | ||||
| 생물학적 활성 | JST-TfR09 (10 ng/well-200 ng; 48 h) reduces viability of MT2, Su9T1, and KK1, and this cell death is inhibited by ferrostatin-1 [1]. JST-TfR09 (100 ng/mL; 48 h) downregulates TFR1, FTH1, and FTL, upregulates IRP2 and NCOA4, and induces lysosome-dependent ferritin degradation and autophagy in ED, KK1, and MT2 ATLL cell lines [1]. JST-TfR09 (100 ng/mL; 48 h) increases intracellular ferrous iron, ROS, and lipid peroxidation (MDA) levels, key hallmarks of ferroptosis, in Su9T1, MT2, ST1, SO4, KK1, and ED ATLL cell lines and MOLT4, JURKAT T-ALL cell lines [1]. JST-TfR09 induces in vitro toxicity to human erythroblasts differentiated from CD34 hematopoietic stem cells at concentrations greater than 156 ng/mL [2]. . Increased cell viability to almost 80% in MT2, Su9T1, and KK1 ATLL cell lines when co-treated with ferrostatin-1. Western Blot Analysis [1] Cell Line: ATLL cell lines (ED, KK1, MT2) Concentration: 100 ng/mL; 25 uM Aloxistatin () + 50 uM Pepstatin A () (pretreatment); 10 uM MG132 () (pretreatment) Incubation Time: 48 h (JST-TfR09); 24 h (pretreatment prior to JST-TfR09) Result: Decreased TFR1, FTH1, and FTL protein levels in ED and KK1 cells. Increased IRP2 and NCOA4 protein levels in ED and KK1 cells. Prevented JST-TfR09-induced ferritin degradation in cells pretreated with lysosomal inhibitors, while proteasomal inhibitor pretreatment did not. Increased LC3-II expression relative to LC3-I in cells, indicating autophagy activation, which was blocked by lysosomal inhibitor co-treatment. | ||||
| 테스트된 응용 분야 | FCM | ||||
| 타겟 | CD71, T9, TFRC, TR, TfR, TfR1, Transferrin receptor 1, Transferrin receptor protein 1, Transferrin receptor protein 1, serum form, Trfr, p90, sTfR | ||||
| 내독소 수준 | < 10 EU/mg | ||||
| 순도 | >95% as determined by SDS-PAGE. | ||||
| 정제 | Protein A/G purified from cell culture supernatant. | ||||
| 등록번호 | P02786 | ||||
| RRID | Anti-Human Transferrin R/TfR Reference Antibody (JST-TFR09, RUO) (abinScience Cat# HY036096, RRID:AB_3751763) |
||||
| 형태 | Liquid | ||||
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
||||
| 제품 사용 정보 |
| ||||
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||
| 대체 이름 | JST-TFR09, JSTTFR09, JSTTFR09 | ||||
| 배경 | Transferrin receptor protein 1 (CD71/TFRC) is a ~84 kDa protein. Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. The apotransferrin-receptor complex is then recycled to the cell surface with a return to neutral pH and the concomitant loss of affinity of apotransferrin for its receptor. Transferrin receptor is necessary for development of erythrocytes and the nervous system. A second ligand, the hereditary hemochromatosis protein HFE, competes for binding with transferrin for an overlapping C-terminal binding site. 1. Senyilmaz, D. et al. (2015) Nature 525, 124-8. PMID: 26214738 2. Jabara, HH. et al. (2016) Nature genetics 48, 74-8. PMID: 26642240 | ||||
| 참고 문헌 | 1. Fauzi YR, et al. Anti-transferrin receptor antibody (JST-TFR09/PPMX-T003) induces ferroptosis in adult T-cell leukemia/lymphoma (ATLL) cells. Biochem Biophys Res Commun. 2025;756:151564. [HY036096] 2. Daniels-Wells TR, et al. Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma. Cancers (Basel). 2023;15(6):1816. Published 2023 Mar 17. [HY036096] |
||||
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. | ||||
| Isotype Control | Human IgG1, lambda Isotype Control antibody (HyHEL-10) (HP248107) |

SDS-PAGE for Research Grade Anti-Human CD71/TFRC (JST-TFR09).

Flow-cytometry using APC anti-human CD71 antibody. U937 cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD71 monoclonal antibody (Catalog: HY036096, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

Flow-cytometry using FITC anti-human CD71 antibody. U937 cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD71 monoclonal antibody (Catalog: HY036096, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

Flow-cytometry using PE anti-human CD71 antibody. U937 cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CD71 monoclonal antibody (Catalog: HY036096, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.








+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206

中文
English
한국어
日本語
Español
Français
Русский